SRNE
Sorrento Therapeutics Inc
Price:  
0.31 
USD
Volume:  
176,993,280.00
United States | Biotechnology
Valuation
Overview
Financials
Forecast
Compare
Historical Price
SolvencyDividends
Transactions
People

SRNE WACC - Weighted Average Cost of Capital

The WACC of Sorrento Therapeutics Inc (SRNE) is 7.3%.

The Cost of Equity of Sorrento Therapeutics Inc (SRNE) is 208.15%.
The Cost of Debt of Sorrento Therapeutics Inc (SRNE) is 5.50%.

Range Selected
Cost of equity 168.00% - 248.30% 208.15%
Tax rate 0.60% - 1.60% 1.10%
Cost of debt 4.00% - 7.00% 5.50%
WACC 5.5% - 9.1% 7.3%
WACC

SRNE WACC calculation

Category Low High
Long-term bond rate 3.9% 4.4%
Equity market risk premium 4.6% 5.6%
Adjusted beta 35.68 43.47
Additional risk adjustments 0.0% 0.5%
Cost of equity 168.00% 248.30%
Tax rate 0.60% 1.60%
Debt/Equity ratio 107.02 107.02
Cost of debt 4.00% 7.00%
After-tax WACC 5.5% 9.1%
Selected WACC 7.3%